944275-21-2

Basic information

• Product Name: 2-(2-CHLOROPHENYL)-1,3-THIAZOLE-4-CARBOXYLIC ACID
• Synonyms: 2-(2-CHLOROPHENYL)-1,3-THIAZOLE-4-CARBOXYLIC ACID
• CAS NO: 944275-21-2
• Molecular Formula: C₁₀H₆ClNO₂S
• Molecular Weight: 239.67814
• Mol File: 944275-21-2.mol

Chemical Properties

• Melting Point: 192-194
• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-(2-CHLOROPHENYL)-1,3-THIAZOLE-4-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-CHLOROPHENYL)-1,3-THIAZOLE-4-CARBOXYLIC ACID(944275-21-2)
• EPA Substance Registry System: 2-(2-CHLOROPHENYL)-1,3-THIAZOLE-4-CARBOXYLIC ACID(944275-21-2)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 944275-21-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-(2-Chlorophenyl)-1,3-thiazole-4-carboxylic acid is used as a building block for the synthesis of various drugs and pharmaceuticals. Its unique chemical structure allows for the creation of a wide range of bioactive molecules, making it an essential component in drug discovery and development.
Used in Drug Synthesis:
As a key intermediate, 2-(2-Chlorophenyl)-1,3-thiazole-4-carboxylic acid is used in the synthesis of various therapeutic agents. Its presence in the molecular structure can enhance the pharmacological properties of the resulting compounds, contributing to their efficacy and safety.
Used in Specialty Chemicals and Materials Manufacturing:
Beyond its applications in the pharmaceutical industry, 2-(2-Chlorophenyl)-1,3-thiazole-4-carboxylic acid may also find use in other industrial sectors. Its unique properties can be leveraged in the manufacturing of specialty chemicals and materials, where it can contribute to the development of innovative products with specific applications.

Upstream product

• 1311864-08-0 methyl 2-(2-chlorophenyl)thiazole-4-carboxylate 
• 1113-59-3 bromopyruvic acid 
• 15717-17-6 2-chlorothiobenzamide 
• 609-66-5 2-chlorobenzamide 
• 132089-36-2 ethyl 2-(2-chlorophenyl)thiazole-4-carboxylate 

Relevant articles and documents

Purple acid phosphatase inhibitors as leads for osteoporosis chemotherapeutics

Purple acid phosphatases (PAPs) are metalloenzymes that catalyse the hydrolysis of phosphate esters under acidic conditions. Their active site contains a Fe(III)Fe(II) metal centre in mammals and a Fe(III)Zn(II) or Fe(III)Mn(II) metal centre in plants. In humans, elevated PAP levels in serum strongly correlate with the progression of osteoporosis and metabolic bone malignancies, which make PAP a target suitable for the development of chemotherapeutics to combat bone ailments. Due to difficulties in obtaining the human enzyme, the corresponding enzymes from red kidney bean and pig have been used previously to develop specific PAP inhibitors. Here, existing lead compounds were further elaborated to create a series of inhibitors with Ki values as low as ～30 μM. The inhibition constants of these compounds were of comparable magnitude for pig and red kidney bean PAPs, indicating that relevant binding interactions are conserved. The crystal structure of red kidney bean PAP in complex with the most potent inhibitor in this series, compound 4f, was solved to 2.40 ? resolution. This inhibitor coordinates directly to the binuclear metal centre in the active site as expected based on its competitive mode of inhibition. Docking simulations predict that this compound binds to human PAP in a similar mode. This study presents the first example of a PAP structure in complex with an inhibitor that is of relevance to the development of anti-osteoporotic chemotherapeutics.

Utilization of an Active Site Mutant Receptor for the Identification of Potent and Selective Atypical 5-HT2C Receptor Agonists

Agonism of the 5-HT2C receptor represents one of the most well-studied and clinically proven mechanisms for pharmacological weight reduction. Selectivity over the closely related 5-HT2A and 5-HT2B receptors is critical as their activation has been shown to lead to undesirable side effects and major safety concerns. In this communication, we report the development of a new screening paradigm that utilizes an active site mutant D134A (D3.32) 5-HT2C receptor to identify atypical agonist structures. We additionally report the discovery and optimization of a novel class of nonbasic heterocyclic amide agonists of 5-HT2C. SAR investigations around the screening hits provided a diverse set of potent agonists at 5-HT2C with high selectivity over the related 5-HT2A and 5-HT2B receptor subtypes. Further optimization through replacement of the amide with a variety of five- and six-membered heterocycles led to the identification of 6-(1-ethyl-3-(quinolin-8-yl)-1H-pyrazol-5-yl)pyridazin-3-amine (69). Oral administration of 69 to rats reduced food intake in an ad libitum feeding model, which could be completely reversed by a selective 5-HT2C antagonist.

Synthesis, Activity, and Docking Study of Novel Phenylthiazole-Carboxamido Acid Derivatives as FFA2 Agonists

Free fatty acid receptor 2 (FFA2), also known as GPR43, is activated by short-chain fatty acids (SCFAs) that are mainly produced by the gut microbiota through the fermentation of undigested carbohydrates and dietary fibers. FFA2 currently appears to be a

A catch-and-release strategy for the combinatorial synthesis of 4-acylamino-1,3-thiazoles as potential CDK5 inhibitors

Two-dimensional libraries of 4-acylamino-1,3-thiazoles 9 were prepared via Curtius rearrangement of 1,3-thiazole-4-carbonyl azides 6, trapping of the intermediate isocyanates with oxime resin, and thermal regeneration of the isocyanates from the washed resin in the presence of nucleophiles. Several compounds proved to be selective inhibitors of CDK5/p25 versus the closely homologous CDK2/cyclin A enzyme, with the best analogue (43) possessing over 100-fold selectivity.